Clinical Trial Detail

NCT ID NCT01712217
Title A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Astex Pharmaceuticals
Indications

non-small cell lung carcinoma

Therapies

Crizotinib

AT13387

Age Groups: adult

Additional content available in CKB BOOST